Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.36 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680990 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TSHRL3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL3680993 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TSHRL3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL5033579 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TSHRL3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL12667950 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TSHRL3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL4485950 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TSHRL3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL4460390 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TSHRL3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL4485945 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TSHRL3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL3745167 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TSHRL3MBTL1SMN1; SMN2KDM4E | |
| Bromide SCHEMBL1770934 | 0.99 | ALDH1A1 (0.40) | ALDH1A1TSHRL3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL4472116 | 0.92 | ALDH1A1 (0.41) | ALDH1A1TSHRL3MBTL1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12521393-B2 | Cytotoxicity targeting chimeras for CCR2-expressing cells | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-13 | — | — | US | disclosed |
| EP-4640280-A2 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-10-29 | — | — | EP | disclosed |
| EP-4384223-B1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-10-01 | — | — | EP | disclosed |
| US-20250136722-A1 | CYTOTOXICITY TARGETING CHIMERAS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| US-20250057958-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-20 | — | — | US | disclosed |
| US-20240325392-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| EP-4384224-A1 | CYTOTOXICITY TARGETING CHIMERAS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023161881-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023017483-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | WO | disclosed |
| US-20070032541-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT J | 2007-02-08 | — | — | US | disclosed |
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CARTER PEROY H | 2007-02-08 | — | — | US | disclosed |
| US-7163937-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| US-7087604-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060135503-A1 | Cyclic derivatives as modulators of chemokine receptors activity | CHERNEY ROBERT J | 2006-06-22 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| US-20040235836-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-23 | — | — | US | disclosed |
| US-20030216434-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | ALDH1A1 1402/4885TSHR 851/4885L3MBTL1 4803/4885 |
| US-20040235836-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | ALDH1A1 1095/4885TSHR 1088/4885L3MBTL1 4779/4885 |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | ALDH1A1 1039/4885TSHR 1052/4885L3MBTL1 4835/4885 |
| US-20250057958-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | ALDH1A1 4466/4885TSHR 1629/4885L3MBTL1 442/4885 |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | ALDH1A1 827/4885TSHR 1726/4885L3MBTL1 4606/4885 |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | ALDH1A1 1627/4885TSHR 778/4885L3MBTL1 201/4885 |
| US-20060135503-A1 | Cyclic derivatives as modulators of chemokine receptors activity | CCL11, CCR1, CCL2 | ALDH1A1 1022/4885TSHR 1191/4885L3MBTL1 4046/4885 |
| US-20250136722-A1 | CYTOTOXICITY TARGETING CHIMERAS | HAVCR2, CD47, CYTH3 | ALDH1A1 4788/4885TSHR 1405/4885L3MBTL1 463/4885 |
| US-20070032541-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | ALDH1A1 1195/4885TSHR 855/4885L3MBTL1 4848/4885 |
| US-20240325392-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | ALDH1A1 4466/4885TSHR 1629/4885L3MBTL1 442/4885 |
| US-20030216434-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCR1, CCL11, CXCR1 | ALDH1A1 948/4885TSHR 1318/4885L3MBTL1 4155/4885 |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | ALDH1A1 1402/4885TSHR 851/4885L3MBTL1 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.